| Symbol | AMLX |
|---|---|
| Name | AMYLYX PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 43 THORNDIKE STREET, CAMBRIDGE, Massachusetts, 02141, United States |
| Telephone | +1 617 682-0917 |
| Fax | — |
| — | |
| Website | https://www.amylyx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001658551 |
| Description | Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Additional info from NASDAQ: |
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
Read moreZeiher Bernhardt G 🟢 acquired 24.4K shares (1 derivative) of Amylyx Pharmaceuticals, Inc. (AMLX) at $14.31 Transaction Date: Jun 04, 2026 | Filing ID: 261647
Read moreFirestone Karen 🟢 acquired 24.4K shares (1 derivative) of Amylyx Pharmaceuticals, Inc. (AMLX) at $14.31 Transaction Date: Jun 04, 2026 | Filing ID: 261641
Read moreQuimi Daphne 🟢 acquired 24.4K shares (1 derivative) of Amylyx Pharmaceuticals, Inc. (AMLX) at $14.31 Transaction Date: Jun 04, 2026 | Filing ID: 261640
Read moreFONTEYNE PAUL R. 🟢 acquired 24.4K shares (1 derivative) of Amylyx Pharmaceuticals, Inc. (AMLX) at $14.31 Transaction Date: Jun 04, 2026 | Filing ID: 261637
Read more(99% Neutral) AMYLYX PHARMACEUTICALS, INC. (AMLX) Announces Regulatory Update
Read moreFirestone Karen 🟢 acquired 3.8K shares of Amylyx Pharmaceuticals, Inc. (AMLX) at $13.51 Transaction Date: May 21, 2026 | Filing ID: 239216
Read moreAmylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
Read more(30% Negative) AMYLYX PHARMACEUTICALS, INC. (AMLX) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05286372 | An Intermediate Size Expanded Access Protocol of AMX0035 for ALS | — | Amyotrophic Lateral Sclerosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07582874 | An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatri… | — | Post-bariatric Hypoglycemia | Available | — | — | ClinicalTrials.gov |
| NCT06747468 | Avexitide for Treatment of Post-Bariatric Hypoglycemia | Phase3 | Post Bariatric Hypoglycemia | Active_Not_Recruiting | 2025-04-29 | 2026-10-01 | ClinicalTrials.gov |
| NCT06665165 | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | Phase1 | ALS | Recruiting | 2025-04-07 | 2027-10-01 | ClinicalTrials.gov |
| NCT06122662 | AMX0035 and Progressive Supranuclear Palsy | Phase2 | Progressive Supranuclear Palsy | Completed | 2023-12-21 | 2025-10-21 | ClinicalTrials.gov |
| NCT05676034 | AMX0035 in Adult Patients With Wolfram Syndrome | Phase2 | Wolfram Syndrome | Active_Not_Recruiting | 2023-03-03 | 2028-05-31 | ClinicalTrials.gov |
| NCT05619783 | Extension Study Evaluating The Safety And Tolerability of AMX0035 | Phase3 | Amyotrophic Lateral Sclerosis | Completed | 2022-12-29 | 2024-10-30 | ClinicalTrials.gov |
| NCT05021536 | Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment | Phase3 | Amyotrophic Lateral Sclerosis | Active_Not_Recruiting | 2021-10-28 | 2026-01-01 | ClinicalTrials.gov |
| NCT04987671 | Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS | Phase1 | ALS | Unknown | 2021-08-05 | 2023-09-01 | ClinicalTrials.gov |
| NCT04516096 | A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrop… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2020-11-22 | 2023-01-31 | ClinicalTrials.gov |
| NCT03533257 | Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment… | Phase2 | Alzheimer Disease | Completed | 2018-09-14 | 2020-11-06 | ClinicalTrials.gov |
| NCT03488524 | Open Label Extension Study of AMX0035 in Patients With ALS | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2018-03-29 | 2021-03-01 | ClinicalTrials.gov |
| NCT03127514 | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2017-06-22 | 2019-11-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Avexitide | Other | Preclinical | Post-bariatric Hypoglycemia | AVAILABLE | NCT07582874 |
| Avexitide | Other | Preclinical | Post-bariatric Hypoglycemia | AVAILABLE | NCT07582874 |
| Avexitide | Other | Preclinical | Post-bariatric Hypoglycemia | AVAILABLE | NCT07582874 |
| Avexitide | Other | Preclinical | Post-bariatric Hypoglycemia | AVAILABLE | NCT07582874 |
| Avexitide | Other | Preclinical | Post-bariatric Hypoglycemia | AVAILABLE | NCT07582874 |
| Avexitide | Other | Preclinical | Post-bariatric Hypoglycemia | AVAILABLE | NCT07582874 |
| AMX0035 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT04516096 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03127514 |
| AMX0035 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03127514 |
| AMX0035 | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT05619783 |
| AMX0035 | Other | Preclinical | Amyotrophic Lateral Sclerosis | APPROVED_FOR_MARKETING | NCT05286372 |
| AMX0035 | Other | Phase PHASE1 | ALS | UNKNOWN | NCT04987671 |
| AMX0035 | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT05021536 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT05021536 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03533257 |
| AMX0035 | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03533257 |
| AMX0035 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03488524 |
| Placebo | Other | Phase PHASE3 | Post Bariatric Hypoglycemia | ACTIVE_NOT_RECRUITING | NCT06747468 |
| Avexitide | Other | Phase PHASE3 | Post Bariatric Hypoglycemia | ACTIVE_NOT_RECRUITING | NCT06747468 |
| Placebo | Other | Phase PHASE1 | ALS | RECRUITING | NCT06665165 |
| AMX0114 | Other | Phase PHASE1 | ALS | RECRUITING | NCT06665165 |
| AMX0035 | Other | Phase PHASE2 | Wolfram Syndrome | ACTIVE_NOT_RECRUITING | NCT05676034 |
| Placebo | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| AMX0035 | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| Placebo | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| AMX0035 | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| Placebo | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| AMX0035 | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| Placebo | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| AMX0035 | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| Placebo | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| AMX0035 | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| Placebo | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| AMX0035 | Other | Phase PHASE2 | Progressive Supranuclear Palsy | COMPLETED | NCT06122662 |
| Avexitide | DRUG | Phase PHASE3 | Post Bariatric Hypoglycemia | ACTIVE_NOT_RECRUITING | NCT06747468 |
| AMX0114 | DRUG | Phase PHASE1 | ALS | RECRUITING | NCT06665165 |
| Placebo | OTHER | Phase PHASE3 | Post Bariatric Hypoglycemia | ACTIVE_NOT_RECRUITING | NCT06747468 |
| AMX0035 | DRUG | Phase PHASE2 | Progressive Supranuclear Palsy | ACTIVE_NOT_RECRUITING | NCT06122662 |